Education
About Us
Working with TipRanks
Follow Us
HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$47.25M
Enterprise Value$35.23M
Total Cash (Recent Filing)$4.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding41,087,870
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$4.75Price Target Upside85.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.53
Revenue Forecast (FY)$2.67M
Bulls Say, Bears Say
Bulls Say
Regulatory De‑riskingTwo 510(k) clearances and rapid resolution of an NSE materially reduce regulatory execution risk for the core software/system. This strengthens pathway credibility with partners and payors, speeding potential commercialization and lowering long‑term approval uncertainty.
Working Product PrototypeA tangible, working 12‑lead patch prototype moves the company from concept to demonstrable product, enabling clinical validation, pilot data generation, and more credible commercial pilots. This reduces technical risk and supports durable progress across regulatory and go‑to‑market steps.
AI & Clinical PartnershipHigh‑quality AI leadership and a Mount Sinai collaboration build proprietary algorithmic and annotated data assets, offering a sustainable competitive moat in diagnostics. Clinically anchored algorithms improve product differentiation and long‑term scalability of diagnostic capabilities.
Bears Say
No Revenue / Large LossesAbsence of revenue coupled with sizable, persistent losses indicates the company has not yet monetized its technology at scale. This structural shortfall creates ongoing financing dependency and raises execution risk for achieving sustainable margins and profitable operations over months to years.
Insufficient Cash RunwayA material mismatch between available cash and projected burn means near‑term capital raising is likely required. Reliance on external funding can dilute shareholders, distract management, or delay trials and commercialization if markets or partners aren’t available on acceptable terms.
ACS Regulatory Pathway UncertaintyUnclear FDA pathway for the ACS/ischemia indication creates timing and cost uncertainty. Need for a pivotal study adds multi‑quarter development and enrollment risk, potentially delaying reimbursement discussions and broader commercial scale beyond initial niche markets.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $47.25M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Mar 12, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.14.
How many shares outstanding does HeartBeam have?
HeartBeam has 41,087,870 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -7.483%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (85.55% Upside)
$4.75 (85.55% Upside)
Insider Transactions
Sold Shares
Worth $895.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-571.06%
Trailing 12-Months
Asset Growth
78.36%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful de‑risking of the underlying technology (two FDA 510(k) clearances, working patch prototype, ALIGN ACS pilot enrollment, AI collaboration with Mount Sinai, and an initial commercial partner) and a disciplined cost posture. However, these operational and clinical achievements are balanced by material near‑term financial risk (only $4.4M cash on hand vs. projected $17M–$19M burn in 2026), uncertain regulatory pathway for the ACS indication, and the need to validate commercial adoption beyond a small concierge initial market. Overall, the company demonstrated strong technical and strategic progress but faces significant execution and funding risks that temper the outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$4.75
▲(85.55% Upside)
Technical Analysis
Ownership Overview
11.57% Insiders
2.87% Mutual Funds
2.15% Other Institutional Investors
80.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---